Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.
Martine Extermann, MD, PhD
Advertisement
Articles by Martine Extermann, MD, PhD
Martine Extermann, MD, PhD, shares advice for selecting among the CDK4/6 available for the treatment of patients with hormone receptor–positive breast cancer.
Martine Extermann, MD, PhD, discusses the utility of single-agent trastuzumab in HER2-positive breast cancer.
Advertisement
Latest Updated Articles
Dr. Extermann on the Significance of Novel Treatment Options in HER2+ Breast CancerPublished: September 28th 2021 | Updated:
- Dr. Extermann on Selecting Among Available CDK4/6 Inhibitors in HR+ Breast Cancer
Published: August 16th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5